This study revealed the characteristics and survival of patients diagnosed with pre-capillary PH, according to new diagnostic criteria proposed at the WSPH 2018.
The borderline pre-capillary PH group accounted for 3.2% (22 in 683) of the total patient population who underwent their first RHC and 4.3% of all pre-capillary PH patients (22 in 511). The borderline PH group was 8.6% (50 in 581) of total PH patients. The majority of the borderline pre-capillary PH group belonged to Group 3 and 4.
Most of the previous studies focused on patients with mPAP 25>mPAP>20 mmHg, the so-called “borderline PH,” and did not focus on the pre-capillary nature. The percentage of borderline PH patients was 4.2–18% among all patients and 4.5–22.6% of all patients with mPAP > 20 mmHg [4],[5],[6]. Assad et al. showed that the percentage of patients with mPAP between 19 and 24 mmHg among all patients, including Non-PH patients (20.1%), was 18% and that the majority of them belonged to Group 2 because over 70% patients had cardiovascular disease [4]. Douschan et al. found that 11.7% of all patients, including those without PH (35.2%), had borderline PH [6]. In their study, 20.3% of patients belonged to Group 2 with overt PH, and patients with borderline PH and patients with overt PH showed a higher risk of cardiac disease. These results suggest that the main background factor of these patients was cardiac disease. However, in these studies detailed demographic data, including number of patients without PH, were not known [4],[5],[6]. Another study showed that the total percentage of borderline PH patients was only 4.2% in total, including Non-PH patients (5.7%) [6]. In that study, among borderline PH and patients without PH, a relatively lower percentage of left heart disease (16.2%) and a relatively higher percentage of respiratory disease (29.7%) were found. However, the background status of all patients, including those with overt PH, is not known (Table 6).
In our study, the number of borderline PH group patients, including PH Group 1 to 5, was 8.6%, lower than that reported in Assad’s and Douschan’s studies (22.6% and 18.1%, respectively) (Table 1), and the majority of the total patients belonged to Group 3 (14.6%) and 4 (55.6%). We can explain the relatively higher ratio of these groups since our PH center is associated with respiratory medicine and is one of the high-volume PEA centers in Japan. In our study, the ratio of borderline PH is relatively high in Group 3. Similarly, a study of severe COPD patients who underwent lung transplantation also showed that the majority had a mild elevation of mPAP (20-25 mmHg) [7]; therefore, the majority of patients with severe lung disease tended to have a mild elevation of mPAP. On the other hand, in Group 4, our data showed that the ratio of borderline PH was low. The Papworth hospital study, which is another PEA center, reported chronic thromboembolic disease with mPAP < 25 mmHg in only 42 of 1019 patients (4.1%) who underwent PEA [8].
The higher percentage of Group 4 patients in our center may explain the lower percentage of the borderline PH group in total. Overall, the number of patients who met the new diagnostic criteria depended on their background status.
Regarding baseline characteristics, in addition to hemodynamics, the PaO2, PvO2, and AaDO2 were better in the borderline pre-capillary PH group than in the conventional pre-capillary PH group. Lower PaCO2 in Group 1 of the conventional PH group could suggest the hyperventilation is compensating for gas exchange impairment.
Several studies have shown little correlation between ventilatory function and severity of PH in patients with lung disease [9],[10],[11]. Similarly, in our study, there was no significant difference in ventilatory function between the conventional and the borderline pre-capillary PH groups in Group 3.
In Study 1, the survival of the conventional PH group was worse than that of the borderline PH group. Similarly, in Study 2, the survival of the conventional pre-capillary PH group was worse than that of the borderline pre-capillary PH group, though no significant difference between the borderline PH group and the non-PH group was observed.
Previous data suggested that mild elevation of PH is associated with poor prognosis in idiopathic pulmonary fibrosis [12] or chronic obstructive pulmonary disease [13],[14]. Assad et al. also showed poor prognosis in patients with borderline PH, and the majority of patients seemed to be in Group 2 [4]. Douchan et al. revealed poorer prognosis and increased cardiopulmonary comorbidities in patients with mPAP of 17 - 26 mmHg than for those patients with mPAP < 17 mmHg [5]. They chose patients having similar background status in both the PH and non-PH groups. Although a report including patients with relatively heterogeneous background diseases also showed poor prognosis of borderline PH patients, the difference in prognosis between overt PH and borderline PH patients was detected when they focused on patients in Group 1 [6]. In our study, Group 3 cases had poor prognosis, even in the non-PH group. Additional analysis showed that the number of Non-PH patients was higher from 1999–2009 than that from 2010–2020. This means that Non-PH patients may not have received better treatment than those diagnosed in 2010-2020. In addition, the number of patients who died of malignant disease and underwent lung transplantation was higher in the non-PH group. These underlying conditions may have affected the poor prognosis of the non-PH group in Group 3. The prognosis of patients with slightly increased mPAP could not only be determined by their hemodynamics but also by patients' background conditions. Accordingly, prospective studies are needed to evaluate whether such patients should be prescribed vasodilators.
Limitations
This was a retrospective single-center study, and the sample size was relatively small to evaluate the pre-capillary PH group effectively. Furthermore, our PH center specializes in respiratory medicine. This may have affected the patient cohort. In Group 3, we could not examine extensive lung disease by computed tomography. In the present study, follow-up data after any treatment intervention was not analyzed because there were insufficient data to evaluate the change in patient status.